Evolus (NASDAQ: EOLS) licenses Profhilo skin-quality injectable for U.S. market
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Evolus, Inc. entered into an exclusive License, Supply and Distribution Agreement with IBSA Institut Biochimique SA to develop, commercialize and distribute Profhilo®, an injectable hyaluronic acid product for skin-quality applications, in the United States aesthetics and dermatology markets.
Evolus will fund and manage U.S. development, clinical and regulatory work to seek FDA approval, then purchase product from IBSA under a transfer-price model with periodically adjustable terms. The agreement has no upfront or milestone payments, includes minimum purchase requirements starting in the fourth year after commercial launch, and runs for an initial 15-year term from first FDA approval with optional 5-year renewals. Management describes Profhilo® as a market-leading skin quality injectable abroad that complements Evolus’ existing neurotoxin and dermal filler portfolio and is not expected to change previously communicated 2026 and 2028 financial targets.
Positive
- None.
Negative
- None.
Insights
Evolus adds a proven skin-quality injectable via a low-cash, long-term U.S. license.
Evolus secured exclusive U.S. rights to Profhilo®, a hyaluronic acid injectable focused on skin quality rather than volume. IBSA supplies the product while Evolus handles U.S. development, regulatory work and commercialization, aligning with its existing injectable aesthetics infrastructure.
The economics use a transfer-price model with no upfront or milestone payments, which conserves cash and targets gross margins consistent with Evolus’ long-term framework. Minimum purchase obligations begin in the fourth year after commercial launch and can trigger loss of exclusivity or termination if unmet, tying long-term rights to sales performance.
The initial 15-year term starting at first FDA approval, plus five-year renewal options, provides long runway if the product is approved and adopted. The company states the agreement is not expected to affect its previously communicated 2026 and 2028 financial outlook, so near-term financial impact appears modest, with potential longer-term portfolio benefits depending on U.S. uptake.
8-K Event Classification
3 items: 1.01, 7.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Initial term length: 15 years
Renewal term length: 5-year terms
Profhilo treatments administered: More than 4.8 million
+4 more
7 metrics
Initial term length
15 years
From first FDA approval of Profhilo in the U.S.
Renewal term length
5-year terms
Successive renewals after initial 15-year term
Profhilo treatments administered
More than 4.8 million
Worldwide since launch in 2015
Profhilo country availability
More than 70 countries
Global presence of Profhilo brand
IBSA employee count
Over 2,500 personnel
Global workforce of IBSA
IBSA country reach
Over 90 countries
Markets where IBSA products are available
Minimum purchases start
Fourth year
Beginning in the fourth year after commercial launch
Key Terms
License, Supply and Distribution Agreement, transfer-price model, emerging growth company, forward-looking statements, +2 more
6 terms
License, Supply and Distribution Agreement regulatory
"entered into a License, Supply and Distribution Agreement (the “Agreement”)"
transfer-price model financial
"purchase the Initial Product from IBSA under a transfer-price model"
A transfer-price model is the method a company uses to set the internal prices charged for goods, services, intellectual property or financing when they move between different parts of the same multinational business. It matters to investors because those internal charges determine where profit and tax liabilities are reported, which affects reported margins, tax costs and regulatory scrutiny—think of it like how a family divides a shared bill between members to decide who paid what.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
forward-looking statements regulatory
"This press release contains forward-looking statements as defined"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
skin quality financial
"injectable hyaluronic acid product for skin-quality applications"
aesthetic injectable market financial
"redefining the aesthetic injectable market for the next generation"
FAQ
What agreement did Evolus (EOLS) sign regarding Profhilo in the U.S.?
Evolus signed an exclusive License, Supply and Distribution Agreement with IBSA to develop, commercialize and distribute Profhilo® in the U.S. aesthetics and dermatology fields. Evolus will handle U.S. development, regulatory activities, and commercialization while IBSA supplies product under a transfer-price model.
Does Evolus pay upfront or milestone fees in the IBSA Profhilo deal?
The agreement does not require Evolus to make any upfront or milestone payments to IBSA. Economics are structured through a transfer-price model for product supply, which management says is designed to support gross margins consistent with Evolus’ long-term financial framework.
How long is the Profhilo licensing agreement between Evolus (EOLS) and IBSA?
The initial term is 15 years from the first FDA approval of Profhilo® in the United States. After that, the agreement may renew for successive five-year terms, subject to its conditions, giving Evolus a potentially long commercialization horizon if the product is approved.
What purchase commitments does Evolus have under the Profhilo agreement?
Minimum purchase requirements begin in the fourth year following commercial launch of Profhilo® in the U.S. If Evolus fails to meet these thresholds, its exclusive rights can be converted to non-exclusive or the agreement may be terminated, subject to certain exceptions outlined in the contract.
Will the Profhilo partnership change Evolus’ financial outlook for 2026 and 2028?
Evolus states the agreement is not expected to impact its previously communicated 2026 revenue, operating expense or operating profit outlook, or its previously communicated 2028 revenue or profitability targets. This suggests management views the deal as financially neutral to its existing guidance assumptions.
How does Profhilo fit into Evolus (EOLS) existing aesthetics portfolio?
Profhilo® targets skin quality—hydration, elasticity and smoothness—rather than volume or contour, complementing Evolus’ neurotoxin Jeuveau® and Evolysse® dermal fillers. Management views skin quality injectables as a fast-growing, underpenetrated U.S. segment that broadens its injectable offerings to meet more patient needs.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 7, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(949 ) 284-4555
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
(Nasdaq Global Market) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01 Entry into a Material Definitive Agreement.
IBSA License Agreement - Profhilo®
On July 7, 2026, Evolus, Inc. (the “Company”) and IBSA Institut Biochimique SA (“IBSA”) entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which IBSA granted to the Company an exclusive right and license to develop, commercialize and distribute Profhilo®, an injectable hyaluronic acid product for skin-quality applications (the “Initial Product”), in the United States for use in the aesthetics and dermatological fields (the “Field”). The Agreement also provides the Company with rights to negotiate frights to negotiate for certain additional products in the Profhilo brand family and related line extensions in the Field in the United States.
The Company will be responsible, at its sole expense, for U.S. development, clinical and regulatory activities intended to support U.S. Food and Drug Administration (“FDA”) approval of the Initial Product and will hold any resulting U.S. regulatory approval and related regulatory materials. Following FDA approval, the Company will purchase the Initial Product from IBSA under a transfer-price model, the terms of which are subject to periodic adjustment as set forth in the Agreement. The Agreement is also subject to minimum purchase requirements beginning in the fourth year following commercial launch of the Initial Product, and failure to meet such requirements may result in a conversion of the Company’s exclusive rights to non-exclusive rights or termination of the Agreement, subject to certain exceptions. The Agreement does not require the Company to make any upfront payment or milestone payments to IBSA.
The initial term of the Agreement is fifteen (15) years from the first FDA approval of the Initial Product. The Agreement may renew for successive five (5)-year terms, subject to the terms of the Agreement.
The Agreement contains various representations and warranties, covenants and other provisions that are customary for a transaction of this nature. The representations, warranties and covenants contained in the Agreement were made only for purposes of the Agreement and as of specific dates, were solely for the benefit of the parties to the Agreement, and may be subject to limitations agreed upon by the parties. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Agreement instead of establishing these matters as facts.
The foregoing is a summary of the terms of the Agreement and is qualified in its entirety by reference to the Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
Item 7.01 Regulation FD Disclosure.
On July 8, 2026, the Company issued a press release announcing the execution of the Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |||||||
| 99.1 | Press Release of Evolus, Inc., dated July 8, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Evolus, Inc. | ||||||||
Dated: July 8, 2026 | /s/ David Moatazedi | |||||||
David Moatazedi | ||||||||
President and Chief Executive Officer | ||||||||
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
NEWPORT BEACH, Calif., July 8, 2026 – Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo® in the United States.
Profhilo® is the market-leading injectable in Europe for skin quality, with global brand recognition and availability in more than 70 countries. Profhilo® has a strong track record of clinical performance and commercial success across international markets, with more than 4.8 million treatments administered worldwide since its launch in 2015. The product has achieved broad adoption and is well established as the market leader in the injectable skin quality market. The addition of Profhilo® further enhances Evolus’ injectable portfolio and expands the company’s presence into one of the fastest growing and underpenetrated segments in aesthetics.
Skin quality treatments represent a significant unmet need and growth opportunity in the U.S. and a complementary segment to neurotoxins and dermal fillers, addressing increasing consumer demand for natural-looking, regenerative aesthetic outcomes. Unlike traditional hyaluronic acid injectables that are designed primarily to restore volume, contour, or facial structure, Profhilo® features a unique hyaluronic acid formulation intended for superficial application to improve overall skin quality, including hydration, elasticity, and smoothness. This differentiated approach addresses a distinct patient need and supports a more refined aesthetic outcome that is increasingly favored by patients and practitioners.
“Profhilo® represents an exciting new chapter for Evolus as we expand into skin quality, one of the fastest growing and most innovative segments in injectable aesthetics,” said David Moatazedi, President and Chief Executive Officer of Evolus. “As one of the most recognized and clinically validated products in its category globally, Profhilo® is a natural complement to our portfolio, addressing a distinct and rapidly growing area of consumer demand. We believe skin quality represents the next frontier in injectable aesthetics in the United States, and with our established commercial infrastructure and digital platform, Evolus is uniquely positioned to help define and accelerate the growth of this emerging category while continuing to build the industry’s leading performance beauty company.”
“We are pleased to partner with Evolus to bring Profhilo® to the U.S.,” said Salvatore Cincotti, General Manager of IBSA. “Evolus has demonstrated a unique ability to build consumer-focused aesthetic brands and execute in the U.S. market. We believe this collaboration creates a strong opportunity to expand access to Profhilo® and establish the skin quality category with practitioners and patients in the world’s largest aesthetics market.”
Profhilo® is based on a unique hyaluronic acid formulation designed to improve skin hydration, elasticity, and overall skin quality. The product has been used in millions of treatments globally, reflecting its
established role in clinical practice and providing a strong foundation for introduction into the U.S. market, where demand for minimally invasive aesthetic treatments continues to grow.
The U.S. injectable skin quality category is in early stages compared to Europe. Evolus believes this represents a substantial opportunity to expand the overall aesthetic injectable market by addressing a distinct patient need that complements existing neurotoxin and dermal filler treatments. In more developed international markets, particularly across Europe, skin quality injectables have become a routine component of aesthetic treatment plans, highlighting the long-term growth potential for this category in the U.S.
Under the terms of the agreement, Evolus will be responsible for development activities required for U.S. regulatory approval, as well as commercialization of the product following approval. The agreement reflects Evolus’ disciplined, capital-efficient approach to business development, with no upfront payments. The economics are structured through a transfer-price model designed to support gross margins consistent with Evolus’ long-term financial framework. The agreement is not expected to impact the company’s previously communicated 2026 revenue, operating expense or operating profit outlook, or its previously communicated 2028 revenue or profitability targets.
The addition of Profhilo® further builds on Evolus’ strategy of expanding across key injectable categories, including neurotoxins, dermal fillers, and now skin quality, enabling the company to address a broader range of patient needs and strengthen its partnership with aesthetic practices. By building a portfolio of differentiated products and leveraging its customer-centric commercial model, Evolus continues to advance its leadership in performance beauty and focus on delivering sustainable, long-term value creation.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
About IBSA
IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. It employs over 2,500 personnel worldwide, its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. More information at www.ibsagroup.com
Forward-Looking Statements
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future or anticipated events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that
are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, or other comparable terms intended to identify statements about the future. The company’s forward-looking statements include, but are not limited to, statements related to the anticipated benefits of the licensing and distribution agreement with IBSA; the planned development, regulatory approval and commercialization of Profhilo® in the United States; the expected timing and success of the U.S. product launch and market reception; the anticipated growth, size and underpenetration of the U.S. skin quality injectable category and the broader aesthetic injectable market; the expected complementary fit of Profhilo® with the company's existing neurotoxin and dermal filler portfolio; the anticipated economics of the agreement, including the transfer-price model and its expected impact on gross margins consistent with the company's long-term financial framework; the company's competitive positioning and market leadership expectations; the company's global commercial expansion strategy; and the company's financial guidance and ability to deliver sustainable, long-term value creation.
The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, our reliance on consumer discretionary spending, unfavorable global economic conditions including trade disputes, tariffs and regulatory actions on imports, uncertainties related to customer and consumer adoption of Jeuveau® and Estyme®/Evolysse®, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse® Hyaluronic Acid (HA) gels in the U.S. and Estyme® HA gels in Europe, our ability to maintain regulatory approvals of Jeuveau® and Evolysse® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve and/or maintain regulatory approval for the Evolysse® HA gel products in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the Securities and Exchange Commission on or about May 4, 2026. These filings can be accessed online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections.
Jeuveau®, Nuceiva®, and Evolysse® are registered trademarks of Evolus, Inc.
Estyme® and Cold-X ® are registered trademarks of Symatese Aesthetics S.A.S.
Profhilo® is a registered trademark of IBSA Institut Biochimique SA.
###
Investors:
Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications
Phone: (248) 202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com